Solomon H. Snyder Department of Neuroscience, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Department of Biophysics and Biophysical Chemistry, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Nat Struct Mol Biol. 2024 Nov;31(11):1669-1679. doi: 10.1038/s41594-024-01328-0. Epub 2024 Jun 4.
Excitatory neurotransmission is principally mediated by α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA)-subtype ionotropic glutamate receptors (AMPARs). Negative allosteric modulators are therapeutic candidates that inhibit AMPAR activation and can compete with positive modulators to control AMPAR function through unresolved mechanisms. Here we show that allosteric inhibition pushes AMPARs into a distinct state that prevents both activation and positive allosteric modulation. We used cryo-electron microscopy to capture AMPARs bound to glutamate, while a negative allosteric modulator, GYKI-52466, and positive allosteric modulator, cyclothiazide, compete for control of the AMPARs. GYKI-52466 binds in the ion channel collar and inhibits AMPARs by decoupling the ligand-binding domains from the ion channel. The rearrangement of the ligand-binding domains ruptures the cyclothiazide site, preventing positive modulation. Our data provide a framework for understanding allostery of AMPARs and for rational design of therapeutics targeting AMPARs in neurological diseases.
兴奋性神经递质传递主要由α-氨基-3-羟基-5-甲基-4-异恶唑丙酸(AMPA)型离子型谷氨酸受体(AMPAR)介导。负变构调节剂是一种治疗候选药物,可抑制 AMPAR 激活,并通过未解决的机制与正变构调节剂竞争来控制 AMPAR 功能。在这里,我们表明变构抑制将 AMPAR 推向一种独特的状态,从而阻止 AMPAR 的激活和正变构调节。我们使用冷冻电子显微镜捕获与谷氨酸结合的 AMPAR,同时负变构调节剂 GYKI-52466 和正变构调节剂 cyclothiazide 竞争控制 AMPAR。GYKI-52466 结合在离子通道环上,并通过将配体结合域与离子通道解耦来抑制 AMPAR。配体结合域的重排破坏了 cyclothiazide 结合位点,阻止了正变构调节。我们的数据为理解 AMPAR 的变构作用以及针对神经疾病中 AMPAR 的治疗药物的合理设计提供了框架。